Compare Oklo Inc (OKLO) vs 10X Genomics Inc (TXG) Price & Performance

OKLO trades at $41.51, up 0.97% today but remains in a significant downtrend with a 42% decline year-to-date. The stock shows bearish technical signals with negative profitability metrics including -8.87% ROE and consistent quarterly losses. Recent news highlights participation in a government nuclear power program for AI data centers, providing potential catalysts amid ongoing regulatory challenges and execution risks.

Despite analyst optimism with a $90.88 consensus target representing 119% upside, OKLO faces substantial execution and regulatory hurdles. The company burns significant cash with -$138.77M EBITDA while relying on financing activities. Long-term potential exists in nuclear energy demand, but near-term volatility and losses require careful risk assessment for investors.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.